Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.80 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | PIR | O00625 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | STK16 | O75716 | 1/20 | 0.44 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | FES | P07332 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | YES1 | P07947 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11971846 | 0.89 | BRAF (1.00) | BRAF | |
| SCHEMBL11971999 | 0.88 | BRAF (0.79) | BRAFABL1LCK | |
| SCHEMBL11971689 | 0.87 | BRAF (0.77) | BRAFABL1LCK | |
| SCHEMBL11971751 | 0.87 | BRAF (0.80) | BRAFABL1LCK | |
| SCHEMBL11971892 | 0.86 | BRAF (0.75) | BRAFABL1LCK | |
| SCHEMBL11971788 | 0.85 | BRAF (0.74) | BRAFABL1LCK | |
| SCHEMBL11992425 | 0.85 | BRAF (0.74) | BRAF | |
| SCHEMBL11971525 | 0.84 | BRAF (0.73) | BRAFABL1LCK | |
| SCHEMBL11971760 | 0.83 | BRAF (0.71) | BRAFABL1LCK | |
| SCHEMBL8222871 | 0.82 | BRAF (0.80) | BRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214811-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. | 2012-08-23 | — | — | US | disclosed |
| EP-2470511-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011025965-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214811-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885BMPR1B 4031/4885PLK4 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.